AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18765504
Drug: Warfarin exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin exposure (1-year time window using case-time-control approach)
Trial: 11391748
Drug: Intravenous amantadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amantadine (200 mg)
Trial: 8607888
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral pamidronate/day
Trial: 1393807
Drug: Peribulbar injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar injection (group 1)
Trial: 1393807
Drug: Retrobulbar injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar injection (group 2)
Trial: 2856908
Drug: Cimetidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1.0 mg/kg X h)
Trial: 2856908
Drug: Ranitidine (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (0.16 mg/kg X h)
Trial: 30782696
Drug: Continuous high-flow
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous high-flow nasal oxygen therapy (usual care)
Trial: 11961629
Drug: Local wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local wound infiltration with 10 ml of 0.5% bupivacaine (group I, n = 50)
Trial: 11961629
Drug: Instillation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of the extraperitoneal space with 40 ml of 0.25% bupivacaine (group II, n = 50)
Trial: 16988209
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg)
Trial: 10510158
Drug: Pantoprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (80 mg)
Trial: 7493428
Drug: Water restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water restriction (200 ml/day) during low-sodium diet
Trial: 7493428
Drug: Hydrated group
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrated group (1800 ml/day water intake) during low-sodium diet
Trial: 1372508
Drug: Penicillin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (5 mu twice, 6 hours apart)
Trial: 1372508
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (without penicillin or placebo)
Trial: 3876579
Drug: Analgesic electrical
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic electrical stimulation (AES)
Trial: 15480323
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for 1 year
Trial: 9059210
Drug: Continuous brachial
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous brachial plexus infusion of butorphanol 6 mg with 0.5% mepivacaine
Trial: 9059210
Drug: Bolus of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus of butorphanol 1 mg with 1.5% mepivacaine and continuous brachial plexus infusion of 0.5% mepivacaine with butorphanol 6 mg
Trial: 3512124
Drug: Moricizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine (10 mg/kg/day)
Trial: 18775020
Drug: AZD7371 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7371 20 mg
Trial: 18775020
Drug: AZD7371 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7371 5 mg
Trial: 16214830
Drug: ivabradine 7.5
RxNorm normalized name: ivabradine 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 7.5 mg bid
Trial: 16214830
Drug: ivabradine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 10 mg bid
Trial: 16214830
Drug: ivabradine 5
RxNorm normalized name: ivabradine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 5 mg bid
Trial: 16214830
Drug: atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 50 mg od
Trial: 10503809
Drug: Aminoguanidine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoguanidine (two dose levels)
Trial: 1777372
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 or 50 mg twice daily)
Trial: 6118768
Drug: normal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal treatment (control)
Trial: 31544381
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with comprehensive rehabilitation therapy
Trial: 31544381
Drug: Comprehensive rehabilitation
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive rehabilitation therapy alone (Control group)
Trial: 27996217
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training (ET) program, 12-week, twice a week, 60-minute sessions
Trial: 25367691
Drug: R. emodi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R. emodi capsules (two times a day, two days before menstruation and continued for the first three days of menstruation)
Trial: 25367691
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid capsules (three times a day on the same protocol)
Trial: 19299239
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg/day orally)
Trial: 19299239
Drug: Exemestane (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25 mg/day orally)
Trial: 17534819
Drug: Topical levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical levofloxacin (three times on the day before surgery and seven times on the day of surgery)
Trial: 17534819
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin (200 mg twice on the day before surgery and 200 mg at 3 hours before surgery)
Trial: 17534819
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical and oral levofloxacin (according to the above schedules)
Trial: 15486815
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg acarbose three times a day for eight weeks
Trial: 7863754
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who did not attend treatment regularly (36 patients)
Trial: 7863754
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who attended treatment regularly but had missed at least one treatment (50 patients)
Trial: 30644326
Drug: Ropinirole (agonist)
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ropinirole (agonist)
Trial: 22981241
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate 10 mg for 60 days
Trial: 20212518
Drug: Nortriptyline (tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (tricyclic antidepressant)
Trial: 16414143
Drug: Amlodipine and
RxNorm normalized name: amlodipine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine and ramipril added to previous antihypertensive treatment for 12 weeks
Trial: 1740491
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (1 mg/day, orally) for 5 or 15 days
Trial: 1740491
Drug: Progesterone (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (5-10 mg/day, im, for 2 days) added after RU 486
Trial: 10268816
Drug: Modeling plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modeling plus rehearsal (treatment group)
Trial: 29241520
Drug: Dementia-specific training
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dementia-specific training program for nurses using a mobile phone applet, details on dosage and duration not specified.
Trial: 23052610
Drug: Pandemic influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic influenza A/H1N1 vaccine
Trial: 19968580
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg dutasteride
Trial: 19968580
Drug: 5.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg dutasteride
Trial: 19968580
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg dutasteride daily for 2‐4 weeks
Trial: 19968580
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication for patients)
Trial: 15383199
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg plus Lovastatin 20 mg
Trial: 15383199
Drug: Lovastatin administration
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin administration alone
Trial: 11530717
Drug: Respiratory biofeedback
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory biofeedback therapy using a handheld capnometry device for 4 weeks
Trial: 9624543
Drug: Ceftibuten (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten (400 mg od for 5 days)
Trial: 9624543
Drug: Amoxycillin/clavulanate (250/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate (250/125 mg tds for 10 days)
Trial: 7936843
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) 300 U/kg three times a week s.c. and iron at 6 mg/kg/d
Trial: 7936843
Drug: Iron at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron at 3 mg/kg/d (control group)
Trial: 29198057
Drug: Individual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual physical therapy alone
Trial: 29198057
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (individual physical therapy alone)
Trial: 23633679
Drug: Selenium 200
RxNorm normalized name: SELENIUM 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium 200 µg/d for 3 months
Trial: 23576623
Drug: cabergoline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cabergoline (3 mg/day)
Trial: 23576623
Drug: levodopa (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa (300 mg/day)
Trial: 11731181
Drug: Gelestra (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelestra (17 beta-estradiol gel 0.6 mg/g)
Trial: 11731181
Drug: Estraderm TTS
RxNorm normalized name: ESTRADERM TTS
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estraderm TTS 50 (transdermal delivery system)
Trial: 7996377
Drug: Itraconazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (5 and then 10 mg/kg per day)
Trial: 7996377
Drug: Historical group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical group (daily ketoconazole prophylaxis)
Trial: 3209324
Drug: RePUVA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RePUVA therapy (PUVA started with retinoids, gradually increased to 4 j/cm2 by the beginning of the third week)
Trial: 20102633
Drug: Iron fortified
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron fortified breakfast cereal (16 mg iron per serve) with two ZESPRI(R) GOLD kiwifruit
Trial: 20102633
Drug: Iron fortified
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron fortified breakfast cereal (16 mg iron per serve) with a banana (low ascorbic acid and carotenoid content)
Trial: 18257146
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day DRI
Trial: 18257146
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day DRI
Trial: 11515638
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education programme administered by schoolteachers
Trial: 2899102
Drug: Cetirizine 2
RxNorm normalized name: cetirizine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 2 HCl, 10 mg once a day
Trial: 30234740
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (initiated after day 7)
Trial: 30234740
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (initiated within 24 hours)
Trial: 19934445
Drug: Face‐to‐face training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face‐to‐face training sessions using music therapy
Trial: 16136768
Drug: Levocetirizine 5
RxNorm normalized name: Levocetirizine 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 5 mg once daily for 4 weeks
Trial: 9917116
Drug: Lovastatin 10
RxNorm normalized name: lovastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 10 mg/d, titrated to 20 mg/d and 40 mg/d at 8 and 16 weeks, respectively.
Trial: 7743786
Drug: Imipramine drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine drug therapy (Drug)
Trial: 7743786
Drug: Interpersonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal therapy (IPT‐M)
Trial: 7743786
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IPT‐M and Drug
Trial: 2344059
Drug: 1% rectal
RxNorm normalized name: Proctofoam 1% Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% rectal methohexital (25 mg/kg)
Trial: 2344059
Drug: 10% rectal
RxNorm normalized name: Cortifoam 10% Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% rectal methohexital (25 mg/kg)
Trial: 24131528
Drug: Automated, interactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated, interactive cognitive behaviour training (CB training), completed weekly with email reminders.
Trial: 17596903
Drug: Drug court
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug court intervention (outpatient treatment with drug court supervision)
Trial: 17596903
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment without drug court supervision
Trial: 16878198
Drug: No sealing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sealing (same treatment as Group II)
Trial: 14526927
Drug: Uranium gastrointestinal
RxNorm normalized name: uranium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uranium gastrointestinal absorption (f1) values
Trial: 10871912
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone replacement therapy (HRT) and bisphosphonate
Trial: 10871912
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy with testosterone
Trial: 10871912
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alendronate and parathyroid hormone (PTH)
Trial: 10871912
Drug: Tiludronate and
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiludronate and PTH, calcitonin and PTH, calcitonin and anabolic steroids
Trial: 1474172
Drug: DI‐Antalvic (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DI‐Antalvic (30 mg dextropropoxyphene and 400 mg paracetamol per capsule, 6 capsules/day for 1 week)
Trial: 1474172
Drug: Efferalgan‐Codeine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efferalgan‐Codeine (30 mg codeine and 500 mg paracetamol per tablet, 6 tablets/day for 1 week)
Trial: 6725915
Drug: Immunoreactive measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoreactive measurement of trypsin excretion
Trial: 29231298
Drug: Four-hand-needling therapy
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-hand-needling therapy (Sanjian (LI 3), Wailaogong (EX‐UE 8), Zhongzhu (TE 3), Houxi (SI 3) on the affected side)
Trial: 29231298
Drug: Routine needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine needling therapy at neck‐Jiaji (EX‐B 2) on bilateral C4, C5 and C6
Trial: 24096683
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir (DTG) 50 mg
Trial: 24096683
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (CLcr >90 mL/min)
Trial: 19020154
Drug: Intranasal ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketorolac 10 mg
Trial: 12798613
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of anti-hepatitis B vaccine (20 microg, doses at 0, 15, and 30 days)
Trial: 12798613
Drug: Intradermal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal administration of anti-hepatitis B vaccine (20 microg, doses at 0, 15, and 30 days)
Trial: 11355929
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all‐trans retinoic acid (ATRA) and conventional anthracycline‐ARA‐C chemotherapy (CT)
Trial: 11355929
Drug: Prolonged maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged maintenance treatment with ATRA and low dose CT
Trial: 11355929
Drug: Rapid onset
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid onset of CT and/or high dose steroids for ATRA syndrome
Trial: 28538556
Drug: Juvéderm Voluma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juvéderm Voluma (2 ml injected)
Trial: 24231251
Drug: Relative telomere
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relative telomere length (RTL) measured by quantitative PCR on blood or buccal cell DNA
Trial: 21989182
Drug: Adjuvant fluorouracil/folinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant fluorouracil/folinic acid (FU/FA) treatment
Trial: 11777094
Drug: Sequential mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential mixed frequency stimulation from a standard device
Trial: 8495604
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg EPA-E
Trial: 8495604
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg EPA-E
Trial: 8495604
Drug: Placebo (1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1656 mg olive oil)
Trial: 30388160
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg DNA-IIV3
Trial: 24317366
Drug: E+R (epigallocatechin-gallate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E+R (epigallocatechin-gallate 282 mg day(‐1) + resveratrol 200 mg day(‐1))
Trial: 24317366
Drug: E+R+S (epigallocatechin-gallate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E+R+S (epigallocatechin-gallate 282 mg day(‐1) + resveratrol 200 mg day(‐1) + soy isoflavones 80 mg day(‐1))
Trial: 22992814
Drug: Anterior route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior route of injection
Trial: 22992814
Drug: Lateral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral route of injection
Trial: 22992814
Drug: Posterior route
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior route of injection
Trial: 22992814
Drug: Posterior route
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior route of injection in females
Trial: 22992814
Drug: Posterior route
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior route of injection in males
Trial: 20560909
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 1000 μg